William Blair analyst Andrew Brackmann has maintained their bullish stance on SERA stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Brackmann has given his Buy rating due to a combination of factors that suggest a promising future for Sera Prognostics. The company is making strides in increasing physician awareness and adoption of its PreTRM test, as well as gaining payer coverage and support for guideline inclusion. These efforts are crucial for the long-term success of the test, which is expected to see significant opportunities in the market.
Furthermore, Sera Prognostics is progressing with pilot programs in two Medicaid plans, showing notable traction in states with high preterm birth rates. Although the company does not anticipate an immediate increase in volume and revenue, the ongoing market-building efforts and the accumulation of supportive data for the PreTRM test underpin a positive outlook. This strategic positioning leads to the conclusion that Sera Prognostics holds substantial potential for future growth, justifying the Buy rating.
According to TipRanks, Brackmann is a 2-star analyst with an average return of 0.1% and a 41.67% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as Exact Sciences, Qiagen, and QuidelOrtho.